Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
Journal of Clinical Oncology2018Vol. 37(3), pp. 178–189
Citations Over TimeTop 1% of 2018 papers
Stephen Johnston, Shannon Puhalla, Duncan Wheatley, Alistair Ring, Peter Barry, Chris Holcombe, Jean Francois Boileau, Louise Provencher, André Robidoux, Mothaffar F. Rimawi, Stuart McIntosh, I. Shalaby, Robert C. Stein, Michael P. Thirlwell, David Dolling, James P. Morden, Claire Snowdon, Sophie Perry, Chester Cornman, Leona Batten, Lisa K. Jeffs, Andrew Dodson, Vera Martins, Arjun Modi, C. Kent Osborne, Katherine L. Pogue–Geile, Maggie C.U. Cheang, Norman Wolmark, Thomas B. Julian, Kate Fisher, Mairead MacKenzie, Maggie Wilcox, Cynthia Huang Bartlett, María Koehler, Mitch Dowsett, Judith M. Bliss, Samuel A. Jacobs
Abstract
Adding palbociclib to letrozole significantly enhanced the suppression of malignant cell proliferation (Ki-67) in primary ER-positive BC, but did not increase the clinical response rate over 14 weeks, which was possibly related to a concurrent reduction in apoptosis.
Related Papers
- → Palbociclib and Letrozole in Advanced Breast Cancer(2016)2,879 cited
- → Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up(2019)426 cited
- → Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer(2023)25 cited
- → Cost-Utility Analysis of Palbociclib, Ribociclib and Letrozole in the First Line Treatment of Metastatic Breast Cancer in Iran Using Partitioned Survival Model(2021)